It’s good to see how we got here...... Whoever our partner is ? They LOVE IT!!! Partnered with.......BIG PHARMA?
November 18, 2020
Adva-27a into clinical trials. It is anticipated that the clinical trials will be for Stage IV pancreatic cancer indication and will be performed at McGill University’s Jewish General Hospital in Montreal, Canada. “We are delighted to be working with our new Montreal-Based partner and their fully integrated team of experts in chemical synthesis, cell culture assays and mice studies,” said Camille Sebaaly, CFO of Sunshine Biopharma.
They now have a mass drug producer in China. Has our partner been doing human trials????
December 8, 2020
“today announced that it has ordered a new batch of Adva-27a from its manufacturer in China.“
The material will be delivered to the laboratories of Sunshine Biopharma’s drug development partner in Montreal (Canada). Sunshine plans to use the material to conduct testing on various types of cancer cells that overproduce Topoisomerase II (TopII). Following these cell culture studies, Sunshine will proceed to performing studies on mice harboring tumors of human origin with TopII amplification. TopII is an essential cell cycle enzyme that is amplified in approximately 4% of all human cancers. “All cancer types that have amplification of the Topoisomerase II gene are potential new targets for our Adva-27a,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
“This is an additional application for our Adva-27a beyond the original multidrug resistance indication,” he added.
News 
Market Data 
Discover 
